---
title: "300942.SZ (300942.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300942.SZ/news.md"
symbol: "300942.SZ"
name: "300942.SZ"
parent: "https://longbridge.com/en/quote/300942.SZ.md"
datetime: "2026-05-21T19:30:26.124Z"
locales:
  - [en](https://longbridge.com/en/quote/300942.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300942.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300942.SZ/news.md)
---

# 300942.SZ (300942.SZ) — Related News

### [Exclusive Interview with Zhou Penghui, Founder of PanEn Biotechnology: Development of Cell Therapy Requires Government Funding to Drive Social Capital](https://longbridge.com/en/news/284714214.md)
*2026-04-30T06:59:10.000Z*
> Zhou Penghui, founder of Fanen Biotechnology, emphasized the importance of government funding in the field of cell thera

### [As the "Order No. 818" is about to be implemented, how will strict policy regulation reshape the cell therapy industry?](https://longbridge.com/en/news/283439318.md)
*2026-04-21T04:44:13.000Z*
> The "Regulations on the Management of Clinical Research and Clinical Translational Applications of Biomedical New Techno

### [GENSCRIPT BIO released its 2025 ESG report, leading sustainable growth through systematic governance and innovative practices](https://longbridge.com/en/news/282738104.md)
*2026-04-14T20:01:56.000Z*
> GENSCRIPT BIO released its 2025 ESG report, showcasing its performance and progress in environmental management, social 

### [Yuanxiang China authorized partner's Phase III clinical trial meets standards, enhancing visibility for authorization in the European and American markets](https://longbridge.com/en/news/280558128.md)
*2026-03-26T03:05:07.000Z*
> Yuanxiang Biotechnology (6945-TW) announced that its licensing partner Innovent Biologics has met the targets in the Pha

### [Weimou Biotech goes public in Hong Kong: Competing for the dry eye market, founder Shen Wang simultaneously manages two pharmaceutical companies](https://longbridge.com/en/news/279830042.md)
*2026-03-19T17:02:47.000Z*
> Weimou Biotechnology has submitted an IPO application to the Hong Kong Stock Exchange, competing for the dry eye market.

### [Sun-Novo plans to invest 20 million yuan in Ruiyang Biotechnology](https://longbridge.com/en/news/278371960.md)
*2026-03-09T10:23:02.000Z*
> Sun-Novo plans to invest 20 million yuan in Ruiyang Biotech, acquiring a 1.6721% equity stake after the capital increase

### [Vimian Biotechnology submitted a listing application to the Hong Kong Stock Exchange](https://longbridge.com/en/news/275895293.md)
*2026-02-13T11:56:41.000Z*
> According to Hong Kong Stock Exchange documents, on February 13, Weimou Biotechnology Co., Ltd. submitted a listing appl

### [New Stock News | VIVA BIOTECH files with the Hong Kong Stock Exchange](https://longbridge.com/en/news/275843879.md)
*2026-02-13T03:23:03.000Z*
> According to the Hong Kong Stock Exchange's disclosure on February 13, Weimou Biotechnology (Zhejiang) Co., Ltd. - B (re

### [INNOVENT BIO forecasts that last year's product revenue will increase by approximately 45% year-on-year](https://longbridge.com/en/news/274859781.md)
*2026-02-04T19:36:03.000Z*
> Innovent Bio forecasts that last year's product revenue increased by approximately 45% year-on-year, reaching about 11.9

### [600 million financing exhausted, over 1.1 billion spent on acquisitions, Dongning Bio's "burning money" expansion struggles to achieve profitability](https://longbridge.com/en/news/274835738.md)
*2026-02-04T15:05:08.000Z*
> 600 million financing exhausted, over 1.1 billion spent on mergers and acquisitions, Dongning Bio's "burning money" expa